Cafepharma Today

June 3 2025 - Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech
Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech
Arrowhead commences dosing in Phase I/IIa obesity treatment trial
ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flop
Amid staff cuts, FDA looks to AI to 'optimize' reviews
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

J&J snaps up an NS5A inhibitor from GlaxoSmithKline for hep C cocktail
Fierce Biotech
Tuesday, October 8, 2013 - 9:41am
tags:
JNJ, NS5A Inhibitors, GSK, hepatitis C, simeprevir, GSK2336805
Teva 'very confident' in timeline for generic Advair
The Fly on the Wall
Tuesday, October 8, 2013 - 9:39am
tags:
Teva, Advair, generics
The U.S. House of Representatives votes to fund the FDA until the federal shutdown ends, or until Dec. 15, whichever comes first
Mass Device
Tuesday, October 8, 2013 - 9:37am
tags:
FDA
2 Companies Offering Hope In the Fight Against Parkinson’s Disease
Wall St. Cheat Sheet
Tuesday, October 8, 2013 - 9:07am
tags:
Parkinson's Disease, Acadia, International Stem Cell Corp, pimavanserin, parthenogenesis
FirstWord Lists: Merck & Co. extends its lead atop the 'pharma job cuts' league table
First Word Pharma
Tuesday, October 8, 2013 - 8:44am
tags:
Merck, layoffs
Alnylam advances Development Candidate for ALN-AS1
Yahoo/Fly on the Wall
Tuesday, October 8, 2013 - 8:43am
tags:
Alnylam, ALN-AS1, hepatic porphyrias
Arena - Tracking Belviq Refills
Seeking Alpha
Tuesday, October 8, 2013 - 8:41am
tags:
Belviq, Eisai, Arena Pharmaceuticals, obesity
Pluristem's Promising GvHD Indication Pits It Against Osiris
Seeking Alpha
Tuesday, October 8, 2013 - 8:41am
tags:
Pluristem, graft vs host disease, Osiris, stem cells
Are These 2 High-Flying Biotech Stocks a Buy?
Motley Fool
Tuesday, October 8, 2013 - 8:39am
tags:
Cell Therapeutics, pacritinib, INSYS Therapeutics, Subsys
Supreme Court Rejects Novartis Bid To Hear Punitive Damages Case
Pharmalot
Tuesday, October 8, 2013 - 8:37am
tags:
Novartis, Supreme Court, FDA
Bayer to bring five mid-stage drugs into Phase III by 2015
Reuters
Tuesday, October 8, 2013 - 8:36am
tags:
Bayer, oncology, cardiology, Women's Health
Glaxo Malaria Shot Protects for 18 Months in Africa Study
Bloomberg
Tuesday, October 8, 2013 - 8:35am
tags:
GSK, vaccines, malaria, RTS, S
The Shutdown: An Update on FDA Activities
FDA Law Blog
Tuesday, October 8, 2013 - 8:34am
tags:
FDA
pSivida: Previewing The Possible Effect On The Stock Of The October 17th PDUFA Date For Iluvien
Seeking Alpha
Tuesday, October 8, 2013 - 8:33am
tags:
pSivida, Iluvien, Alimera, diabetic macular edema
Forget drug-sales forecasts, study finds: They're mostly wrong
Fierce Pharma
Monday, October 7, 2013 - 7:39pm
tags:
sales forecasts
Teva's First-To-File Track Record Best Among Peers
Seeking Alpha
Monday, October 7, 2013 - 7:28pm
tags:
Teva, AbbVie
Myriad Genetics Changes How Doctors Treat Patients
Motley Fool
Monday, October 7, 2013 - 7:27pm
tags:
Myriad Genetics, BRCA test, breast cancer, ovarian cancer
Did Pfizer and Ligand Just Get a New Winning Drug Approved?
Wall St. Cheat Sheet
Monday, October 7, 2013 - 7:23pm
tags:
Pfizer, Ligand, Duavee, hot flashes, menopause, osteoporosis
Experts thinks Biogen to likely be able to market Tecfidera in EU, says Leerink
Yahoo/Fly on the Wall
Monday, October 7, 2013 - 11:01am
tags:
Biogen Idec, multiple sclerosis, MS, Europe, Tecfidera
Can Merck Really Revive Itself By Jettisoning Employees?
Forbes
Monday, October 7, 2013 - 10:53am
tags:
layoffs, Merck

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.